Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality. LEARN MORE NOVEL TECHNOLOGY NEW SOLUTION Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell cu...
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial Article Open access 07 August 2024 Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, with nearly 60,000 expected new di...
“OR-gate” CARs that enable T cells to effectively target tumor cells that present either antigen A or antigen B, thus requiring tumor cells to lose both antigens before escaping T-cell detection. Toward the goal of dual-antigen targeting for MM, a CAR incorporating a truncated “a ...
CAR-T cells persisted at a median of 406 days. Soluble BCMA could serve as an ideal biomarker for efficacy monitoring. CS1-BCMA CAR-T cells were clinically active with good safety profiles in patients with RRMM. Clinical trial registration: This study was registered on ClinicalTrials.gov, ...
Creative Biolabs offer a high-quality CellRapeutics™ CAR × TCR Bispecific T Cells Engineering Platform to assist in customers' CART project.
The CD3/CD19 BiTE® is a biopharmaceutical drug known as a Bi-specific T-cell engager for a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It binds to CD19 on cancer cells (e.g. Raji cells) and CD3 on T cells simultaneously,...
Base on this, we performed aphase I trial to assess the safety and efficacy of CD19 and CD20 bispecific CAR T cells to patients with refractory or relapsed CD20 or CD19 positive B‐cell lymphoma. Methods: Adult (≥18 years) patients with pathologically confirmed diagnose of CD20+ or CD19...
BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to mitigate these limitations. Methods We constructed...
Treatment with CD19/22 chimeric antigen receptor CAR T cells induced a promising response in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Haneen Shalabi, DO, an assistant research physician in the pediatric oncology branch at the National Cancer Institute's Center ...
CD123 CAR T cells for the treatment of myelodysplastic syndrome. Exp Hematol. 2019;74(52–63):e3. Google Scholar Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting...